Protagonist Therapeutics, Inc lost $2.05 per diluted share in fiscal year 2025. This represents a decrease of 148.5% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $1.02 per diluted share. The table below carries 12 fiscal years, from 2014 to 2025, and the quarters Protagonist Therapeutics, Inc has filed alongside them.
FY2025 annual
EPS (Diluted)-$2.05
YoY-148.5%
5Y CAGRn/m
Source SEC Filings (10-K/10-Q)Latest period Q2 FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
PTGX EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was Protagonist Therapeutics, Inc's diluted earnings per share in fiscal year 2025?
Protagonist Therapeutics, Inc lost $2.05 per diluted share in fiscal year 2025.
How fast is Protagonist Therapeutics, Inc's diluted earnings per share growing?
Protagonist Therapeutics, Inc (PTGX) diluted earnings per share fell by 148.5% year over year, from $4.23 to -$2.05 in fiscal year 2025.
What is Protagonist Therapeutics, Inc's diluted earnings per share over the last twelve months?
Protagonist Therapeutics, Inc (PTGX) reported $1.02 per diluted share over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Protagonist Therapeutics, Inc's diluted earnings per share changed over the years?
Across the 12 fiscal years this page covers, Protagonist Therapeutics, Inc (PTGX) diluted earnings per share went from -$49.38 in fiscal year 2014 to -$2.05 in fiscal year 2025.
What was Protagonist Therapeutics, Inc's diluted earnings per share in the most recent quarter?
Protagonist Therapeutics, Inc (PTGX) reported $2.29 in diluted earnings per share in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Protagonist Therapeutics, Inc (PTGX) reported on that line in every period on record.
